Respiratory System Agents

• 

  Subject Areas on Research

  • Consensus statement: aerosols and delivery devices. American Association for Respiratory Care. 
  • Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. 
  • LPA1 antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis. 
  • Liquid ventilation. 
  • Management of bronchiolitis in infants and children. 
  • Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis. 
  • Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials. 
  • Stimulation of Respiratory Motor Output and Ventilation in a Murine Model of Pompe Disease by Ampakines.